Your browser does not support iframes.
Teva’s Global Generics Senior Management Team recently visited Teva PLIVA in Croatia.
During the visit, the team held working meetings with global and local management, visited PLIVA’s R&D labs and held a town hall meeting with R&D and RA employees. The town hall was an exciting opportunity for members of senior management to introduce themselves in person. Hafrun Fridriksdottir, EVP, President of Global Generics R&D, reviewed recent activity at Teva. She addressed key developments in generic R&D and a vision for the future, with special emphasis on Zagreb R&D and RA. In addition, Claire Dabreu-Hayling, SVP, Generic R&D - Global Sterile, and Michael Banks, SVP RA Global Generics & OTC, R&D, also discussed the achievements of Zagreb R&D and RA in 2017, and commended their teams for an outstanding effort. In particular, Hafrun thanked employees for their exceptional performance in September 2017, at which time Teva submitted 18 ANDAs for registration in the US. She also noted that Teva’s Zagreb site is recognized as a key element of the Generics R&D organization. These positive results, as well as a new organizational structure for the Global RA Team in Zagreb, were also presented by the management team. In addition, recent progress in implementing new processes and improving results was also recognized.